2020-2027 Here Are The Factors That Can Have A Sizeable Impact On IVIG Market Growth

Intravenous immunoglobulin (IVIG) market to grow at a CAGR of 6.8% between 2015 and 2021. Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), immunodeficiency are the most prominent disease classes, collectively contributing about 53% of the global IVIG market revenue in 2014. Myasthenia Gravis would be the fastest growing segment with a double digit growth during the forecast period, due to the increasing adoption of IVIG as first line treatment. 

Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/325?utm_source=pharmiweb&utm_medium=Niranjan

Intravenous immunoglobulin (IVIG) is the parenteral preparation of purified immunoglobulin derived from large pools of human plasma containing antibodies against a broad spectrum of bacterial and viral agents. The IVIG demand has been growing on account of increased usage in primary immunodeficiency and application in newer indications. The emerging concept of hyper-immune globulin is likely to increase the efficacy of IVIG treatments by providing passive immunity to patients against disease causing agents. Allied Market Research estimates that about 130 tons of IVIG was issued in 2014 and is expected to reach 215 tons by 2021.

On contrary, the side effects associated with the use of IVIG infusion would restrict the market growth to an extent. Moreover, current high cost of IVGI treatment may trigger a shift towards cost effective corticosteroids treatment, restraining the IVIG market growth. However, improved production and purification techniques along with the improved plasma yield would help to overcome cost constraints; eventually supplementing the growth of IVIG market. Furthermore, anticipated approval for Alzheimer’s and Multiple Sclerosis provides growth opportunity for the IVIG market.  

Key finding of the study: 

Chronic inflammatory demyelinating polyneuropathy (CIDP) and the hypogammaglobulinemia are the leading application for IVIG, collectively contributing about 2/5th of the market revenueCongenital AIDS is projected to be one of the fastest-growing application segments at a CAGR 9.3% during the forecast periodNorth America will remain the leading region throughout the forecast period, 2015-2021, closely followed by the Asia-PacificEurope is projected to be the fastest growing IVIG market during 2015-2021

For More Inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/325?utm_source=pharmiweb&utm_medium=Niranjan

Geographically, North America and Asia-Pacific constitute the two largest markets for IVIG, collectively accounted for ~75% of the market revenue in 2014. Higher adoption rates, large patient population, and the presence of largest plasma collection & manufacturing base are the key factors responsible for the growth of IVIG market in these regions. However, the market growth outlook across developing economies is also looking strong, owing to increasing awareness towards immunodeficiency and rare autoimmune diseases, favorable reimbursement initiatives and improved healthcare expenditure.

Grifols S.A., CSL Behring, and Baxter International are identified as top three market players in 2014. Other key IVIG manufacturing companies profiled in the report Baxter international Inc., CSL Behring, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others.

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.